A phase I study of ifosfamide/carboplatin/etoposide/paclitaxel in advanced lung cancer

G. M. Strauss, T. J. Lynch, A. D. Elias, C. Jacobs, D. J. Kwiatkowski, L. N. Shulman, R. W. Carey, M. L. Grossbard, S. Jauss, D. J. Sugarbaker, A. T. Skarin

Research output: Contribution to journalArticlepeer-review

10 Scopus citations


A phase I study was conducted to define the maximally tolerated dose and toxicity profile of the ifosfamide/carboplatin/etoposide/paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) (ICE-T) regimen in advanced lung cancer. This chemotherapy program uses paclitaxel given as a 24-hour continuous infusion in conjunction with full-dose ICE chemotherapy with growth factor support. The dosage of paclitaxel was escalated from 75 to 225 mg/m2. Thirty-four patients have been accrued to date onto this study. Because hematologic dose-limiting toxicity was defined in terms of neutropenia and/or thrombocytopenia exceeding 7 days' duration, no patient demonstrated what was defined by the protocol as dose-limiting toxicity. Nonetheless, substantial hematologic toxicity was observed. Overall, 26% had fever and neutropenia, 56% had grade 4 neutropenia, and 26% had grade 4 thrombocytopenia. In all cases, hematologic toxicity was short term and reversible. While grade 3 and 4 myelosuppression was frequently observed, it was not dose related (in terms of paclitaxel dosage). Nonhematologic toxicity also was not dose related and, with only a few exceptions, was not clinically significant. Among 27 patients evaluable for response, 41% achieved an objective response, including 15% with a complete response. All of five patients with small cell lung cancer responded (including two with a complete response). Among 22 patients with non-small cell lung cancer, 27% achieved an objective response (also including two with a complete response). The results of this study suggest that with growth factor support, it is possible to safely administer full-dose, single-agent paclitaxel in conjunction with full-dose ICE chemotherapy. We will soon be initiating a phase II study of the ICE-T regimen using paclitaxel at 225 mg/m2 as a 24-hour continuous infusion in advanced lung cancer. We will also conduct a phase I study of ICE-T, with paclitaxel administered as a 3-hour continuous infusion.

Original languageEnglish
Pages (from-to)70-74
Number of pages5
JournalSeminars in Oncology
Issue number4 SUPPL. 9
StatePublished - 1995
Externally publishedYes


Dive into the research topics of 'A phase I study of ifosfamide/carboplatin/etoposide/paclitaxel in advanced lung cancer'. Together they form a unique fingerprint.

Cite this